>provided that production cost for the recombinants is low enough<
I think (and hope) that recombinant are cheaper because they do not rely on blood donation however, If OMRI,KAMADA and alike are clever, they can compete by discounting their product considerably.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.